Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Estrogen Receptor-negative Breast Cancer: early-phase trial registry
A small indexed set (5 trials) with no open enrollment listed right now.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · none currently recruiting · #3,391 of 28,707 conditions by registered trial count
Estrogen Receptor-negative Breast Cancer: 5 US clinical trials tracked, none currently recruiting.
Estrogen Receptor-negative Breast Cancer is the subject of 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, running 1 of these trials.
Enrollment posture brief
Registry condition estrogen-receptor-negative-breast-cancer
OPEN 0 | RECR 0% | LATE 0 | EARLY 5 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Estrogen Receptor-negative Breast Cancer has no open enrollment in this registry pull (5 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Estrogen Receptor-negative Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Estrogen Receptor-negative Breast Cancer is recruiting below its size-band peers.
0 of 5 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Estrogen Receptor-negative Breast Cancer research.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Estrogen Receptor-negative Breast Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.
-
Estrogen Receptor-negative Breast Cancer research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Rutgers, The State University of New Jersey
NCT02315196
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
NCT02957968
Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer
National Cancer Institute (NCI)
NCT00516243
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
Indiana University
NCT00577122
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01818063
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Estrogen Receptor-negative Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Estrogen Receptor-negative Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Estrogen Receptor-negative Breast Cancer page
5 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Estrogen Receptor-negative Breast Cancer trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University sponsors the most Estrogen Receptor-negative Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Estrogen Receptor-negative Breast Cancer condition card totals 5 registered trials; most-linked intervention Paclitaxel; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.